Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
InnoCare Pharma Ltd. ( (HK:9969) ) just unveiled an update.
InnoCare Pharma Ltd. announced the successful presentation of phase II clinical data for their drug ICP-488 at the 2025 American Academy of Dermatology Annual Meeting. The study demonstrated that ICP-488, a selective oral TYK2 inhibitor, is highly effective and safe in treating moderate-to-severe plaque psoriasis, showing significant improvement in patients compared to placebo. This advancement positions InnoCare Pharma as a promising player in the dermatology treatment market, potentially impacting its operations and offering new treatment options for stakeholders.
More about InnoCare Pharma Ltd.
InnoCare Pharma Ltd. is a pharmaceutical company focused on the development of innovative drugs, particularly in the field of dermatology. The company is engaged in creating treatments for conditions such as moderate-to-severe plaque psoriasis, with a market focus on providing effective and safe therapeutic options.
YTD Price Performance: 59.31%
Average Trading Volume: 7,504,168
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$14.59B
Find detailed analytics on 9969 stock on TipRanks’ Stock Analysis page.